T-cell Therapy Market to Grow with a CAGR of 9.88% through 2029
Growing advancements
in genetic engineering technologies is expected to drive the Global T-cell
Therapy Market growth in the forecast period, 2025-2029
According to
TechSci Research report, “T-cell Therapy Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2029”, the
Global T-cell Therapy Market stood at USD 2.65 billion in 2023 and is
anticipated to grow with a CAGR of 9.88% in the forecast period, 2025-2029. T-cell
therapy, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapy, has
emerged as a revolutionary approach in the fight against cancer, and several
factors contribute to the burgeoning growth of this market. One of the primary
drivers fueling the expansion of the T-cell therapy market is the rising global
incidence of cancer. According to the World Health Organization (WHO), cancer
is a leading cause of morbidity and mortality worldwide, with an estimated 19.3
million new cancer cases and almost 10 million cancer-related deaths. This alarming prevalence of cancer has necessitated the development of
more effective and targeted therapies, propelling the demand for innovative
treatments like T-cell therapy.
The approval and
commercial success of CAR-T therapies for hematological malignancies, such as
leukemia and lymphoma, represent a significant driver for the T-cell therapy
market. CAR-T therapies involve genetically modifying a patient's T cells to
express chimeric antigen receptors, enabling them to recognize and attack
cancer cells with specific antigens. The success stories of CAR-T therapies
like Kymriah and Yescarta have paved the way for increased investment in
research and development within the T-cell therapy space.
Advancements in
genetic engineering technologies have played a pivotal role in enhancing the
precision and safety of T-cell therapies. The advent of CRISPR-Cas9 technology
has allowed for more accurate and targeted genetic modifications, reducing the
risk of off-target effects and improving the overall therapeutic outcomes. This
has propelled the development of next-generation T-cell therapies, expanding
their applicability to a broader spectrum of cancers.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global T-cell Therapy Market”
The Global
T-cell Therapy Market is segmented into Therapy Type, Indication, Regional
Distribution, And Company.
Based
on the Therapy Type, CAR T-cell therapy emerged as the dominant segment in the
global market for Global Hematology T-cell Therapy in 2023. CAR T-cell
therapies have shown effectiveness across a broader spectrum of cancers
compared to TCR-based and TIL-based therapies. CAR T-cell therapies can be
designed to target a wide range of surface antigens on cancer cells, making
them versatile for different cancer types. In contrast, TCR-based therapies
typically focus on intracellular antigens presented by major histocompatibility
complex (MHC) molecules, limiting their applicability to specific cancer types.
CAR T-cell therapies generally involve a more straightforward manufacturing
process compared to TCR-based therapies, which require the identification and
isolation of specific T-cell receptors. The relative simplicity of CAR T-cell
production has contributed to more streamlined and scalable manufacturing
processes, meeting the growing demand for these therapies. CAR T-cell therapies
were among the first T-cell therapies to gain commercial availability and
widespread adoption. The commercial success of CAR T-cell therapies has
attracted significant investment, fostering research and development in this
field. This has led to a more extensive infrastructure for the production,
distribution, and administration of CAR T-cell therapies, contributing to their
dominance in the market.
Based
on the Indication, hematologic malignancies emerged as the dominant segment in
the global market for Global T-cell Therapy Market in 2023. Solid tumors
present a more complex microenvironment, characterized by immunosuppressive
factors that can hinder the effectiveness of T-cell therapies. Overcoming these
barriers in solid tumors is a significant challenge. While research is ongoing
to optimize T-cell therapies for solid tumors, the current success and focus
have been more pronounced in hematologic malignancies. The regulatory approvals
for CAR T-cell therapies initially focused on hematologic malignancies. These
approvals, coupled with accumulating clinical experience, have established a
foundation for the widespread utilization of T-cell therapies in treating
diseases like leukemia and lymphoma. Physicians and healthcare providers often
gain confidence and familiarity with these therapies through their application
in hematologic indications.
North
America emerged as the dominant player in the
Global T-cell Therapy Market in
2023, holding the largest market share. North America has witnessed substantial
investment and funding in the field of T-cell therapy. Both public and private
funding sources, along with venture capital, have fueled the growth of
companies focused on T-cell therapy development. This financial support has
enabled extensive research, clinical trials, and the commercialization of
T-cell therapies. North America, particularly the United States, has been at the
forefront of early adoption and regulatory approvals for T-cell therapies. The
U.S. Food and Drug Administration (FDA) has played a pivotal role in expediting
the approval process for innovative therapies, including Chimeric Antigen
Receptor T-cell (CAR-T) therapies. The regulatory support and efficient
approval processes have allowed T-cell therapies to reach the market more
rapidly, contributing to North America's leadership.
Major companies
operating in Global T-cell Therapy Market are:
- Novartis AG
- Merck KGaA
- Gilead Sciences Inc.
- TCR2 Therapeutics Inc
- Bluebird Bio Inc.
- Sorrento Therapeutics Inc.
- Fate Therapeutics Inc.
- Pfizer Inc.
- Amgen Inc
- Celgene Corporation
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Global T-cell Therapy Market is primarily propelled by rising incidences of various cancers, fostering demand for innovative and effective cancer treatments. Advances in biotechnology and immunotherapy have fueled the development of T-cell therapies, contributing to market growth. Additionally, increasing investment in research and development, along with collaborations between pharmaceutical companies, academic institutions, and research organizations, plays a pivotal role. The regulatory support for expedited approvals and commercialization of T-cell therapies further stimulates market expansion. Growing awareness about personalized medicine and the potential of T-cell therapies to address unmet medical needs also contributes to the market's upward trajectory” said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“T-cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type (CAR T-cell Therapy, T Cell Receptor (TCR)-based, Tumor Infiltrating Lymphocytes (TIL)-based)), By Indication (Hematologic Malignancies, Solid Tumors, Others), By Region and Competition, 2019-2029F”, has evaluated the future growth potential of Global
T-cell Therapy Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global T-cell Therapy
Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com